All In Biotech

Drug Trial Radar · NCT06013241

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

288

Actual

Start

Oct 30, 2023

Primary completion

Sep 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.

Conditions

  • Chronic Rhinosinusitis Without Nasal Polyps

Interventions

  • BrensocatibDrug

    Film-coated tablet.

  • PlaceboDrug

    Film-coated tablet.

  • Mometasone furoate nasal spray (MFNS)Drug

    Nasal spray suspension.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24Time frame: Baseline and Week 24

Locations

100 sites in 15 countries. Site status is shown where the registry gives one.

  • USA034

    Tucson, Arizona

  • USA002

    Roseville, California

  • USA006

    Upland, California

  • USA016

    Boca Raton, Florida

  • USA019

    Hollywood, Florida

  • USA001

    Miami, Florida

  • USA009

    Tampa, Florida

  • USA031

    Chicago, Illinois

  • USA021

    Chicago, Illinois

  • USA003

    New Albany, Indiana

  • USA035

    Mandeville, Louisiana

  • USA026

    Baltimore, Maryland

  • USA011

    Columbia, Missouri

  • USA024

    St Louis, Missouri

  • USA033

    New York, New York

  • USA028

    Tulsa, Oklahoma

  • USA004

    Tulsa, Oklahoma

  • USA015

    Hershey, Pennsylvania

  • USA023

    Charleston, South Carolina

  • USA022

    North Charleston, South Carolina

  • USA025

    Dallas, Texas

  • USA037

    Fredericksburg, Texas

  • USA029

    Houston, Texas

  • USA018

    Houston, Texas

  • USA030

    San Antonio, Texas

  • USA038

    Tomball, Texas

  • USA005

    Norfolk, Virginia

  • ARG002

    Mar del Plata, Argentina

  • ARG014

    Mendoza, Argentina

  • ARG003

    Mendoza, Argentina

  • ARG016

    Rosario, Argentina

  • ARG008

    Santa Fe, Argentina

  • ARG015

    La Plata, Buenos Aires, Argentina

  • ARG001

    La Plata, Buenos Aires, Argentina

  • ARG006

    Lobos, Buenos Aires, Argentina

  • ARG005

    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

  • ARG012

    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

  • ARG011

    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

  • ARG017

    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

  • ARG013

    San Rafael, Mendoza Province, Argentina

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.